請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56054完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 賴文崧(Wen-Sung Lai) | |
| dc.contributor.author | Da-Zhong Luo | en |
| dc.contributor.author | 羅達中 | zh_TW |
| dc.date.accessioned | 2021-06-16T05:14:08Z | - |
| dc.date.available | 2019-08-25 | |
| dc.date.copyright | 2014-08-25 | |
| dc.date.issued | 2014 | |
| dc.date.submitted | 2014-08-18 | |
| dc.identifier.citation | Abel, K. M., Drake, R., & Goldstein, J. M. (2010). Sex differences in schizophrenia. Int Rev Psychiatry, 22(5), 417-428.
Abi-Dargham, A. (2004). Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol, 7 Suppl 1, S1-5. Abi-Dargham, A., Gil, R., Krystal, J., Baldwin, R. M., Seibyl, J. P., Bowers, M., . . . Laruelle, M. (1998). Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort. Am J Psychiatry, 155(6), 761-767. Abi-Dargham, A., Mawlawi, O., Lombardo, I., Gil, R., Martinez, D., Huang, Y., . . . Laruelle, M. (2002). Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci, 22(9), 3708-3719. Abi-Dargham, A., & Moore, H. (2003). Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist, 9(5), 404-416. Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., . . . Laruelle, M. (2000). Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A, 97(14), 8104-8109. Ackermann, T. F., Kempe, D. S., Lang, F., & Lang, U. E. (2010). Hyperactivity and enhanced curiosity of mice expressing PKB/SGK-resistant glycogen synthase kinase-3 (GSK-3). Cell Physiol Biochem, 25(6), 775-786. Addington, J., & Duchak, V. (1997). Reasons for substance use in schizophrenia. Acta Psychiatr Scand, 96(5), 329-333. Aghdam, S. Y., & Barger, S. W. (2007). Glycogen synthase kinase-3 in neurodegeneration and neuroprotection: Lessons from lithium. Curr Alzheimer Res, 4(1), 21-31. Ago, Y., Tanaka, T., Kita, Y., Tokumoto, H., Takuma, K., & Matsuda, T. (2012). Lithium attenuates methamphetamine-induced hyperlocomotion and behavioral sensitization via modulation of prefrontal monoamine release. Neuropharmacology, 62(4), 1634-1639. Ahmad, A., Schaack, J. B., White, C. W., & Ahmad, S. (2013). Adenosine A2A receptor-dependent proliferation of pulmonary endothelial cells is mediated through calcium mobilization, PI3-kinase and ERK1/2 pathways. Biochem Biophys Res Commun, 434(3), 566-571. Alauddin, M. M. (2012). Positron emission tomography (PET) imaging with (18)F-based radiotracers. Am J Nucl Med Mol Imaging, 2(1), 55-76. Albizu, L., Holloway, T., Gonzalez-Maeso, J., & Sealfon, S. C. (2011). Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptors. Neuropharmacology, 61(4), 770-777. Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P., & Hemmings, B. A. (1996). Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J, 15(23), 6541-6551. Alvarez, G., Munoz-Montano, J. R., Satrustegui, J., Avila, J., Bogonez, E., & Diaz-Nido, J. (2002). Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disord, 4(3), 153-165. Amar, S., Jones, B. C., Nadri, C., Kozlovsky, N., Belmaker, R. H., & Agam, G. (2004). Genetic correlational analysis of glycogen synthase kinase-3 beta and prepulse inhibition in inbred mice. Genes Brain Behav, 3(3), 178-180. Andreasson, S., Allebeck, P., Engstrom, A., & Rydberg, U. (1987). Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet, 2(8574), 1483-1486. Antonini, A., & Leenders, K. L. (1993). Dopamine D2 receptors in normal human brain: effect of age measured by positron emission tomography (PET) and [11C]-raclopride. Ann N Y Acad Sci, 695, 81-85. Aparicio-Legarza, M. I., Davis, B., Hutson, P. H., & Reynolds, G. P. (1998). Increased density of glutamate/N-methyl-D-aspartate receptors in putamen from schizophrenic patients. Neurosci Lett, 241(2-3), 143-146. Arguello, P. A., & Gogos, J. A. (2006). Modeling madness in mice: One piece at a time. Neuron, 52(1), 179-196. Armani, F., Andersen, M. L., Andreatini, R., Frussa-Filho, R., Tufik, S., & Galduroz, J. C. (2012). Successful combined therapy with tamoxifen and lithium in a paradoxical sleep deprivation-induced mania model. CNS Neurosci Ther, 18(2), 119-125. Armstrong, D., & Strange, P. G. (2001). Dopamine D2 receptor dimer formation: Evidence from ligand binding. J Biol Chem, 276(25), 22621-22629. Arraf, Z., Amit, T., Youdim, M. B., & Farah, R. (2012). Lithium and oxidative stress lessons from the MPTP model of Parkinson's disease. Neurosci Lett, 516(1), 57-61. Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., & Moffitt, T. E. (2002). Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ, 325(7374), 1212-1213. Babst, B. A., Ferrieri, R. A., Gray, D. W., Lerdau, M., Schlyer, D. J., Schueller, M., . . . Orians, C. M. (2005). Jasmonic acid induces rapid changes in carbon transport and partitioning in Populus. New Phytol, 167(1), 63-72. Badshah, H., Kim, T. H., Kim, M. J., Ahmad, A., Ali, T., Yoon, G. H., . . . Kim, M. O. (2014). Apomorphine attenuates ethanol-induced neurodegeneration in the adult rat cortex. Neurochem Int. Bajestan, S. N., Sabouri, A. H., Nakamura, M., Takashima, H., Keikhaee, M. R., Behdani, F., . . . Osame, M. (2006). Association of AKT1 haplotype with the risk of schizophrenia in Iranian population. Am J Med Genet B Neuropsychiatr Genet, 141B(4), 383-386. Balu, D. T., Carlson, G. C., Talbot, K., Kazi, H., Hill-Smith, T. E., Easton, R. M., . . . Lucki, I. (2012). Akt1 deficiency in schizophrenia and impairment of hippocampal plasticity and function. Hippocampus, 22(2), 230-240. Balu, D. T., Li, Y., Puhl, M. D., Benneyworth, M. A., Basu, A. C., Takagi, S., . . . Coyle, J. T. (2013). Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. Proc Natl Acad Sci U S A, 110(26), E2400-2409. Barnes, T. R., Mutsatsa, S. H., Hutton, S. B., Watt, H. C., & Joyce, E. M. (2006). Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry, 188, 237-242. Barnett, J. H., Werners, U., Secher, S. M., Hill, K. E., Brazil, R., Masson, K., . . . Jones, P. B. (2007). Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry, 190, 515-520. Bartha, R., Williamson, P. C., Drost, D. J., Malla, A., Carr, T. J., Cortese, L., . . . Neufeld, R. W. (1997). Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry, 54(10), 959-965. Basu, A. C., Tsai, G. E., Ma, C. L., Ehmsen, J. T., Mustafa, A. K., Han, L., . . . Coyle, J. T. (2009). Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior. Mol Psychiatry, 14(7), 719-727. Beaulieu, J. M. (2007). Not only lithium: Regulation of glycogen synthase kinase-3 by antipsychotics and serotonergic drugs. Int J Neuropsychopharmacol, 10(1), 3-6. Beaulieu, J. M. (2012). A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. J Psychiatry Neurosci, 37(1), 7-16. Beaulieu, J. M., Del'guidice, T., Sotnikova, T. D., Lemasson, M., & Gainetdinov, R. R. (2011). Beyond cAMP: The regulation of Akt and GSK3 by dopamine receptors. Front Mol Neurosci, 4, 38. Beaulieu, J. M., & Gainetdinov, R. R. (2011). The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev, 63(1), 182-217. Beaulieu, J. M., Gainetdinov, R. R., & Caron, M. G. (2007). The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci, 28(4), 166-172. Beaulieu, J. M., Gainetdinov, R. R., & Caron, M. G. (2009). Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol, 49, 327-347. Beaulieu, J. M., Marion, S., Rodriguiz, R. M., Medvedev, I. O., Sotnikova, T. D., Ghisi, V., . . . Caron, M. G. (2008). A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell, 132(1), 125-136. Beaulieu, J. M., Sotnikova, T. D., Gainetdinov, R. R., & Caron, M. G. (2006). Paradoxical striatal cellular signaling responses to psychostimulants in hyperactive mice. J Biol Chem, 281(43), 32072-32080. Beaulieu, J. M., Sotnikova, T. D., Marion, S., Lefkowitz, R. J., Gainetdinov, R. R., & Caron, M. G. (2005). An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell, 122(2), 261-273. Beaulieu, J. M., Sotnikova, T. D., Yao, W. D., Kockeritz, L., Woodgett, J. R., Gainetdinov, R. R., & Caron, M. G. (2004). Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA, 101(14), 5099-5104. Beaulieu, J. M., Zhang, X., Rodriguiz, R. M., Sotnikova, T. D., Cools, M. J., Wetsel, W. C., . . . Caron, M. G. (2008). Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci USA, 105(4), 1333-1338. Belcher, A. M., Volkow, N. D., Moeller, F. G., & Ferre, S. (2014). Personality traits and vulnerability or resilience to substance use disorders. Trends Cogn Sci, 18(4), 211-217. Benaiges, I., Serra-Grabulosa, J. M., & Adan, A. (2013). Neuropsychological functioning and age-related changes in schizophrenia and/or cocaine dependence. Prog Neuropsychopharmacol Biol Psychiatry, 40, 298-305. Bendikov, I., Nadri, C., Amar, S., Panizzutti, R., De Miranda, J., Wolosker, H., & Agam, G. (2007). A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr Res, 90(1-3), 41-51. Benes, F. M., & Berretta, S. (2001). GABAergic interneurons: Implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology, 25(1), 1-27. Benes, F. M., Khan, Y., Vincent, S. L., & Wickramasinghe, R. (1996). Differences in the subregional and cellular distribution of GABAA receptor binding in the hippocampal formation of schizophrenic brain. Synapse, 22(4), 338-349. Bermanzohn, P. C., & Siris, S. G. (1992). Akinesia: A syndrome common to parkinsonism, retarded depression, and negative symptoms of schizophrenia. Compr Psychiatry, 33(4), 221-232. Bierut, L. J. (2011). Genetic vulnerability and susceptibility to substance dependence. Neuron, 69(4), 618-627. Blain, S. W., & Massague, J. (2002). Breast cancer banishes p27 from nucleus. Nat Med, 8(10), 1076-1078. Blockx, I., Van Camp, N., Verhoye, M., Boisgard, R., Dubois, A., Jego, B., . . . Van der Linden, A. (2011). Genotype specific age related changes in a transgenic rat model of Huntington's disease. Neuroimage, 58(4), 1006-1016. Blum, B. P., & Mann, J. J. (2002). The GABAergic system in schizophrenia. Int J Neuropsychopharmacol, 5(2), 159-179. Boileau, I., Payer, D., Chugani, B., Lobo, D., Behzadi, A., Rusjan, P. M., . . . Zack, M. (2013). The D2/3 dopamine receptor in pathological gambling: a positron emission tomography study with [11C]-(+)-propyl-hexahydro-naphtho-oxazin and [11C]raclopride. Addiction, 108(5), 953-963. Borroto-Escuela, D. O., Romero-Fernandez, W., Tarakanov, A. O., Marcellino, D., Ciruela, F., Agnati, L. F., & Fuxe, K. (2010). Dopamine D2 and 5-hydroxytryptamine 5-HT((2)A) receptors assemble into functionally interacting heteromers. Biochem Biophys Res Commun, 401(4), 605-610. Boucher, A. A., Arnold, J. C., Duffy, L., Schofield, P. R., Micheau, J., & Karl, T. (2007). Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol. Psychopharmacology (Berl), 192(3), 325-336. Boucher, A. A., Hunt, G. E., Karl, T., Micheau, J., McGregor, I. S., & Arnold, J. C. (2007). Heterozygous neuregulin 1 mice display greater baseline and Delta(9)-tetrahydrocannabinol-induced c-Fos expression. Neuroscience, 149(4), 861-870. Bousman, C. A., Glatt, S. J., Everall, I. P., & Tsuang, M. T. (2009). Genetic association studies of methamphetamine use disorders: A systematic review and synthesis. Am J Med Genet B Neuropsychiatr Genet, 150B(8), 1025-1049. Bouvrais-Veret, C., Weiss, S., Andrieux, A., Schweitzer, A., McIntosh, J. M., Job, D., . . . Martres, M. P. (2007). Sustained increase of alpha7 nicotinic receptors and choline-induced improvement of learning deficit in STOP knock-out mice. Neuropharmacology, 52(8), 1691-1700. Bowers, M. B., & Kantrowitz, J. T. (2007). Elevated plasma dopamine metabolites in cannabis psychosis. Am J Psychiatry, 164(10), 1615-1616. Boydell, J., van Os, J., McKenzie, K., Allardyce, J., Goel, R., McCreadie, R. G., & Murray, R. M. (2001). Incidence of schizophrenia in ethnic minorities in London: ecological study into interactions with environment. BMJ, 323(7325), 1336-1338. Bradbury, T. N., & Miller, G. A. (1985). Season of birth in schizophrenia: a review of evidence, methodology, and etiology. Psychol Bull, 98(3), 569-594. Brady, A. M., McCallum, S. E., Glick, S. D., & O'Donnell, P. (2008). Enhanced methamphetamine self-administration in a neurodevelopmental rat model of schizophrenia. Psychopharmacology (Berl), 200(2), 205-215. Brauer, L. H., & de Wit, H. (1996). Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers. Biol Psychiatry, 39(1), 26-32. Brauer, L. H., Goudie, A. J., & de Wit, H. (1997). Dopamine ligands and the stimulus effects of amphetamine: Animal models versus human laboratory data. Psychopharmacology (Berl), 130(1), 2-13. Brazil, D. P., Yang, Z. Z., & Hemmings, B. A. (2004). Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci, 29(5), 233-242. Breier, A., Su, T. P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., . . . Pickar, D. (1997). Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA, 94(6), 2569-2574. Bressan, R. A., & Pilowsky, L. S. (2000). Imaging the glutamatergic system in vivo – relevance to schizophrenia. European Journal of Nuclear Medicine, 27(11), 1723-1731. Brodie, J. D., Figueroa, E., & Dewey, S. L. (2003). Treating cocaine addiction: From preclinical to clinical trial experience with gamma-vinyl GABA. Synapse, 50(3), 261-265. Brooks, S. P., & Dunnett, S. B. (2009). Tests to assess motor phenotype in mice: A user's guide. Nat Rev Neurosci, 10(7), 519-529. Brown, A. S. (2011). The environment and susceptibility to schizophrenia. Prog Neurobiol, 93(1), 23-58. Brown, A. S., & Derkits, E. J. (2010). Prenatal infection and schizophrenia: A review of epidemiologic and translational studies. Am J Psychiatry, 167(3), 261-280. Brown, A. S., Susser, E. S., Butler, P. D., Richardson, A. R., Kaufmann, C. A., & Gorman, J. M. (1996). Neurobiological plausibility of prenatal nutritional deprivation as a risk factor for schizophrenia. J Nerv Ment Dis, 184(2), 71-85. Brunette, M. F., Drake, R. E., Xie, H., McHugo, G. J., & Green, A. I. (2006). Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull, 32(4), 637-643. Buchsbaum, M. S., Christian, B. T., Lehrer, D. S., Narayanan, T. K., Shi, B., Mantil, J., . . . Mukherjee, J. (2006). D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res, 85(1-3), 232-244. Buckley, P. F. (1998). Substance abuse in schizophrenia: A review. J Clin Psychiatry, 59 Suppl 3, 26-30. Bustamante, E., & Pedersen, P. L. (1977). High aerobic glycolysis of rat hepatoma cells in culture: Role of mitochondrial hexokinase. Proc Natl Acad Sci USA, 74(9), 3735-3739. Cade, J. F. (1949). Lithium salts in the treatment of psychotic excitement. Med J Aust, 2(10), 349-352. Cadogan, A. K., Alexander, S. P., Boyd, E. A., & Kendall, D. A. (1997). Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. J Neurochem, 69(3), 1131-1137. Calabrese, J. R., Fatemi, S. H., & Woyshville, M. J. (1996). Antidepressant effects of lamotrigine in rapid cycling bipolar disorder. Am J Psychiatry, 153(9), 1236. Calipari, E. S., & Ferris, M. J. (2013). Amphetamine mechanisms and actions at the dopamine terminal revisited. J Neurosci, 33(21), 8923-8925. Camins, A., Verdaguer, E., Junyent, F., Yeste-Velasco, M., Pelegri, C., Vilaplana, J., & Pallas, M. (2009). Potential mechanisms involved in the prevention of neurodegenerative diseases by lithium. CNS Neurosci Ther, 15(4), 333-344. Can, A., Blackwell, R. A., Piantadosi, S. C., Dao, D. T., O'Donnell, K. C., & Gould, T. D. (2011). Antidepressant-like responses to lithium in genetically diverse mouse strains. Genes Brain Behav, 10(4), 434-443. Cannon, M., Jones, P. B., & Murray, R. M. (2002). Obstetric complications and schizophrenia: Historical and meta-analytic review. Am J Psychiatry, 159(7), 1080-1092. Cannon, T. D., van Erp, T. G., Bearden, C. E., Loewy, R., Thompson, P., Toga, A. W., . . . Tsuang, M. T. (2003). Early and late neurodevelopmental influences in the prodrome to schizophrenia: Contributions of genes, environment, and their interactions. Schizophr Bull, 29(4), 653-669. Cantor-Graae, E., Nordstrom, L. G., & McNeil, T. F. (2001). Substance abuse in schizophrenia: A review of the literature and a study of correlates in Sweden. Schizophr Res, 48(1), 69-82. Canuso, C. M., Goldstein, J. M., & Green, A. I. (1998). The evaluation of women with schizophrenia. Psychopharmacol Bull, 34(3), 271-277. Carboni, E., Imperato, A., Perezzani, L., & Di Chiara, G. (1989). Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats. Neuroscience, 28(3), 653-661. Cardno, A. G., & Owen, M. J. (2014). Genetic relationships between schizophrenia, bipolar disorder, and schizoaffective disorder. Schizophr Bull, 40(3), 504-515. Cardona-Gomez, P., Perez, M., Avila, J., Garcia-Segura, L. M., & Wandosell, F. (2004). Estradiol inhibits GSK3 and regulates interaction of estrogen receptors, GSK3, and beta-catenin in the hippocampus. Mol Cell Neurosci, 25(3), 363-373. Carlsson, A., Lindqvist, M., & Magnusson, T. (1957). 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature, 180(4596), 1200. Catts, V. S., & Catts, S. V. (2000). Apoptosis and schizophrenia: Is the tumour suppressor gene, p53, a candidate susceptibility gene? Schizophr Res, 41(3), 405-415. Cazorla, M., de Carvalho, F. D., Chohan, M. O., Shegda, M., Chuhma, N., Rayport, S., . . . Kellendonk, C. (2014). Dopamine D2 receptors regulate the anatomical and functional balance of basal ganglia circuitry. Neuron, 81(1), 153-164. Chadman, K. K., Yang, M., & Crawley, J. N. (2009). Criteria for validating mouse models of psychiatric diseases. Am J Med Genet B Neuropsychiatr Genet, 150B(1), 1-11. Chalecka-Franaszek, E., & Chuang, D. M. (1999). Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci USA, 96(15), 8745-8750. Chambers, R. A., Krystal, J. H., & Self, D. W. (2001). A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry, 50(2), 71-83. Chambers, R. A., Sentir, A. M., Conroy, S. K., Truitt, W. A., & Shekhar, A. (2010). Cortical-striatal integration of cocaine history and prefrontal dysfunction in animal modeling of dual diagnosis. Biol Psychiatry, 67(8), 788-792. Chana, G., Bousman, C. A., Money, T. T., Gibbons, A., Gillett, P., Dean, B., & Everall, I. P. (2013). Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis. Front Cell Neurosci, 7, 95. Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis, 40(5), 373-383. Chatziioannou, A. F. (2002). PET scanners dedicated to molecular imaging of small animal models. Mol Imaging Biol, 4(1), 47-63. Chaudhary, L. R., & Hruska, K. A. (2003). Inhibition of cell survival signal protein kinase B/Akt by curcumin in human prostate cancer cells. J Cell Biochem, 89(1), 1-5. Chaytor, N., & Schmitter-Edgecombe, M. (2003). The ecological validity of neuropsychological tests: A review of the literature on everyday cognitive skills. Neuropsychol Rev, 13(4), 181-197. Chen, H. K., Fernandez-Funez, P., Acevedo, S. F., Lam, Y. C., Kaytor, M. D., Fernandez, M. H., . . . Zoghbi, H. Y. (2003). Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell, 113(4), 457-468. Chen, W. S., Xu, P. Z., Gottlob, K., Chen, M. L., Sokol, K., Shiyanova, T., . . . Hay, N. (2001). Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev, 15(17), 2203-2208. Chen, Y. C., Chen, Y. W., Hsu, Y. F., Chang, W. T., Hsiao, C. K., Min, M. Y., & Lai, W. S. (2012). Akt1 deficiency modulates reward learning and reward prediction error in mice. Genes Brain Behav, 11(2), 157-169. Chen, Y. C., & Lai, W. S. (2010). Behavioural phenotyping of dopamine transporter knockdown mice using local small interference RNA. Behav Brain Res, 214(2), 475-479. Chen, Y. W., Kao, H. Y., Min, M. Y., & Lai, W. S. (2014). A sex- and region-specific role of akt1 in the modulation of methamphetamine-induced hyperlocomotion and striatal neuronal activity: Implications in schizophrenia and methamphetamine-induced psychosis. Schizophr Bull, 40(2), 388-398. Chen, Y. W., & Lai, W. S. (2011). Behavioral phenotyping of v-akt murine thymoma viral oncogene homolog 1-deficient mice reveals a sex-specific prepulse inhibition deficit in females that can be partially alleviated by glycogen synthase kinase-3 inhibitors but not by antipsychotics. Neuroscience, 174, 178-189. Chinta, S. J., & Andersen, J. K. (2005). Dopaminergic neurons. Int J Biochem Cell Biol, 37(5), 942-946. Cho, H., Mu, J., Kim, J. K., Thorvaldsen, J. L., Chu, Q., Crenshaw, E. B., 3rd, . . . Birnbaum, M. J. (2001). Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science, 292(5522), 1728-1731. Cho, H., Thorvaldsen, J. L., Chu, Q., Feng, F., & Birnbaum, M. J. (2001). Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem, 276(42), 38349-38352. Chou, Y. H., Halldin, C., & Farde, L. (2006). Clozapine binds preferentially to cortical D1-like dopamine receptors in the primate brain: A PET study. Psychopharmacology, 185(1), 29-35. Chouinard, G., & Jones, B. D. (1980). Neuroleptic-induced supersensitivity psychosis: Clinical and pharmacologic characteristics. Am J Psychiatry, 137(1), 16-21. Chowdhury, R., Guitart-Masip, M., Lambert, C., Dayan, P., Huys, Q., Duzel, E., & Dolan, R. J. (2013). Dopamine restores reward prediction errors in old age. Nat Neurosci, 16(5), 648-653. Choy, K. H., de Visser, Y. P., & van den Buuse, M. (2009). The effect of 'two hit' neonatal and young-adult stress on dopaminergic modulation of prepulse inhibition and dopamine receptor density. Br J Pharmacol, 156(2), 388-396. Cimarosti, H., Zamin, L. L., Frozza, R., Nassif, M., Horn, A. P., Tavares, A., . . . Salbego, C. (2005). Estradiol protects against oxygen and glucose deprivation in rat hippocampal organotypic cultures and activates Akt and inactivates GSK-3beta. Neurochem Res, 30(2), 191-199. Cipriano, M., Haggstrom, J., Hammarsten, P., & Fowler, C. J. (2013). Association between cannabinoid CB(1) receptor expression and Akt signalling in prostate cancer. PLoS One, 8(6), e65798. Cohen, M., Dembling, B., & Schorling, J. (2002). The association between schizophrenia and cancer: A population-based mortality study. Schizophr Res, 57(2-3), 139-146. Cohen, P., & Frame, S. (2001). The renaissance of GSK3. Nat Rev Mol Cell Biol, 2(10), 769-776. Cole, A. R. (2013). Glycogen synthase kinase 3 substrates in mood disorders and schizophrenia. FEBS J, 280(21), 5213-5227. Colin, E., Regulier, E., Perrin, V., Durr, A., Brice, A., Aebischer, P., . . . Saudou, F. (2005). Akt is altered in an animal model of Huntington's disease and in patients. Eur J Neurosci, 21(6), 1478-1488. Colver, A., & Longwell, S. (2013). New understanding of adolescent brain development: Relevance to transitional healthcare for young people with long term conditions. Arch Dis Child, 98(11), 902-907. Conn, P. J., Battaglia, G., Marino, M. J., & Nicoletti, F. (2005). Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci, 6(10), 787-798. Constantinescu, C. C., Coleman, R. A., Pan, M. L., & Mukherjee, J. (2011). Striatal and extrastriatal microPET imaging of D2/D3 dopamine receptors in rat brain with [(1)(8)F]fallypride and [(1)(8)F]desmethoxyfallypride. Synapse, 65(8), 778-787. Counotte, D. S., Smit, A. B., & Spijker, S. (2012). The Yin and Yang of Nicotine: Harmful during development, beneficial in adult patient populations. Front Pharmacol, 3, 180. Court, J. A., Martin-Ruiz, C., Graham, A., & Perry, E. (2000). Nicotinic receptors in human brain: Topography and pathology. J Chem Neuroanat, 20(3-4), 281-298. Coyle, J. T. (2006). Glutamate and schizophrenia: Beyond the dopamine hypothesis. Cell Mol Neurobiol, 26(4-6), 365-384. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature, 378(6559), 785-789. Crow, T. J. (1980). Molecular pathology of schizophrenia: More than one disease process? Br Med J, 280(6207), 66-68. Cryns, K., Shamir, A., Shapiro, J., Daneels, G., Goris, I., Van Craenendonck, H., . . . Steckler, T. (2007). Lack of lithium-like behavioral and molecular effects in IMPA2 knockout mice. Neuropsychopharmacology, 32(4), 881-891. Cummings, J. L., Miller, B., Hill, M. A., & Neshkes, R. (1987). Neuropsychiatric aspects of multi-infarct dementia and dementia of the Alzheimer type. Arch Neurol, 44(4), 389-393. Curley, A. A., Arion, D., Volk, D. W., Asafu-Adjei, J. K., Sampson, A. R., Fish, K. N., & Lewis, D. A. (2011). Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: Clinical, protein, and cell type-specific features. Am J Psychiatry, 168(9), 921-929. Curran, C., Byrappa, N., & McBride, A. (2004). Stimulant psychosis: Systematic review. Br J Psychiatry, 185, 196-204. D'Hooge, R., & De Deyn, P. P. (2001). Applications of the Morris water maze in the study of learning and memory. Brain Res Brain Res Rev, 36(1), 60-90. Daglish, M. R., Williams, T. M., Wilson, S. J., Taylor, L. G., Eap, C. B., Augsburger, M., . . . Nutt, D. J. (2008). Brain dopamine response in human opioid addiction. Br J Psychiatry, 193(1), 65-72. Dahlstrom, A., & Fuxe, K. (1964). Localization of monoamines in the lower brain stem. Experientia, 20(7), 398-399. Dalley, J. W., Fryer, T. D., Brichard, L., Robinson, E. S., Theobald, D. E., Laane, K., . . . Robbins, T. W. (2007). Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science, 315(5816), 1267-1270. Davidson, L. L., & Heinrichs, R. W. (2003). Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: A meta-analysis. Psychiatry Research: Neuroimaging, 122(2), 69-87. Davies, G., Welham, J., Chant, D., Torrey, E. F., & McGrath, J. (2003). A systematic review and meta-analysis of northern hemisphere season of birth studies in schizophrenia. Schizophr Bull, 29(3), 587-593. Davis, K. L., Kahn, R. S., Ko, G., & Davidson, M. (1991). Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry, 148(11), 1474-1486. Daw, N. D., Niv, Y., & Dayan, P. (2005). Uncertainty-based competition between prefrontal and dorsolateral striatal systems for behavioral control. Nat Neurosci, 8(12), 1704-1711. Dayan, P., & Balleine, B. W. (2002). Reward, motivation, and reinforcement learning. Neuron, 36(2), 285-298. de Bartolomeis, A., Buonaguro, E. F., & Iasevoli, F. (2013). Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: From receptor heterodimers to postsynaptic scaffolding and effector proteins. Psychopharmacology (Berl), 225(1), 1-19. de Ferrari, G. V., Chacon, M. A., Barria, M. I., Garrido, J. L., Godoy, J. A., Olivares, G., . . . Inestrosa, N. C. (2003). Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol Psychiatry, 8(2), 195-208. de Jong, M. H., Zemel, D., & Van Gool, A. R. (2013). Clinical aspects of co-morbid schizophrenia and idiopathic Parkinson's disease. Clin Schizophr Relat Psychoses, 8(1), 1-13. de Lacalle, S. (2006). Estrogen effects on neuronal morphology. Endocrine, 29(2), 185-190. de Leon, J., & Diaz, F. J. (2005). A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res, 76(2-3), 135-157. de Wit, H., & Wise, R. A. (1977). Blockade of cocaine reinforcement in rats with the dopamine receptor blocker pimozide, but not with the noradrenergic blockers phentolamine or phenoxybenzamine. Can J Psychol, 31(4), 195-203. de Witte, N. A., Crunelle, C. L., Sabbe, B., Moggi, F., & Dom, G. (2013). Treatment for outpatients with comorbid schizophrenia and substance use disorders: A review. Eur Addict Res, 20(3), 105-114. Delay, J., Deniker, P., & Harl, J. M. (1952). Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP). Ann Med Psychol (Paris), 110(21), 112-117. DeQuardo, J. R., Carpenter, C. F., & Tandon, R. (1994). Patterns of substance abuse in schizophrenia: Nature and significance. J Psychiatr Res, 28(3), 267-275. Dere, E., Huston, J. P., & de Souza Silva, M. A. (2007). The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci Biobehav Rev, 31(5), 673-704. Di Ciano, P., & Everitt, B. J. (2003). The GABA(B) receptor agonist baclofen attenuates cocaine- and heroin-seeking behavior by rats. Neuropsychopharmacology, 28(3), 510-518. Di Forti, M., Lappin, J. M., & Murray, R. M. (2007). Risk factors for schizophrenia--All roads lead to dopamine. Eur Neuropsychopharmacol, 17 Suppl 2, S101-107. Diaz-Cabiale, Z., Vivo, M., Del Arco, A., O'Connor, W. T., Harte, M. K., Muller, C. E., . . . Ferre, S. (2002). Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors. Neurosci Lett, 324(2), 154-158. Dixon, L. (1999). Dual diagnosis of substance abuse in schizophrenia: Prevalence and impact on outcomes. Schizophr Res, 35 Suppl, S93-100. Dixon, L., Haas, G., Weiden, P. J., Sweeney, J., & Frances, A. J. (1991). Drug abuse in schizophrenic patients: Clinical correlates and reasons for use. Am J Psychiatry, 148(2), 224-230. Dluzen, D. E., & Liu, B. (2008). Gender differences in methamphetamine use and responses: A review. Gend Med, 5(1), 24-35. Doherty, M. D., & Pickel, V. M. (2000). Ultrastructural localization of the serotonin 2A receptor in dopaminergic neurons in the ventral tegmental area. Brain Res, 864(2), 176-185. Downward, J. (1998). Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol, 10(2), 262-267. Durroux, T. (2005). Principles: A model for the allosteric interactions between ligand binding sites within a dimeric GPCR. Trends Pharmacol Sci, 26(7), 376-384. Eaton, W. W. (1985). Epidemiology of schizophrenia. Epidemiol Rev, 7, 105-126. Edwards, S., & Koob, G. F. (2013). Escalation of drug self-administration as a hallmark of pers | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56054 | - |
| dc.description.abstract | 思覺失調症是一複雜的神經精神疾患，其疾病好發年紀在青少年晚期以及成年早期。過去的證據指出思覺失調症的候選基因之ㄧ-AKT1同時也是亞基安非他命濫用的候選基因。除此之外，越來越多的案例指出思覺失調症共病物質濫用的普遍性以及物質(藥物)濫用如何加重思覺失調症相關症狀。近來，越來越多的研究著墨於Akt1基因缺損如何受到性別差異的影響導致出不同的行為異常或神經傳導物上的改變。本研究利用Akt1缺損小鼠，欲配合長期甲基安非他命的施打，觀察其行為，神經傳導物質活性與表現量以及藥物治療操弄，來深入探討思覺失調症的成病因子以及尋找有潛力的治療藥物。實驗ㄧ，欲分析不同年齡層是否影響Akt1對於多巴胺二型受體的活性及其差異，使用放射性同位素配合正子斷層掃描以利觀察。實驗發現，只有成年公鼠的多巴胺二型受體活性受到影響，且根據不同的基因型或是環境因子操控的有無，其活性產生不同的改變。除此之外也發覺這影響並非來自多巴胺或是多巴胺二型受體本身表現量的改變，推測應該是來自於Akt1缺損導致的結果。實驗二使用GSK3相關抗憂鬱藥物-鋰鹽，成功治療或減輕Akt1基因缺損母鼠的異常行為，以期提供病患ㄧ有效的治療方向與發展。本研究闡釋了多巴胺受體本身活性的重要性來推測思覺失調症可能的致病因子之ㄧ，也展示鋰鹽對於思覺失調症相關行為缺陷的治療潛力。 | zh_TW |
| dc.description.abstract | Schizophrenia is a complex neuropsychiatric disorder and its onset generally occurs in late adolescence or early adulthood. Accumulating evidence from human genetic and animal studies suggests that AKT1 is a susceptibility gene for both schizophrenia and methamphetamine (Meth) use disorder. Comorbid substance abuse in schizophrenia has been consistently reported and substance abuse may also exacerbate schizophrenia-related symptoms. Recently, the sex-specific role of Akt1 had been reported that the modulation of Meth-induced hyperlocomotion and striatal neuronal activity in male mice, whereas the behavior deficits such as depression-like behavior and sensorimotor gating function in female mice. Otherwise, recent study also revealed that Akt1-deficit mice were insensitive to antipsychotic drugs, but GSK3 (a key downstream kinase for Akt1) inhibitor could have therapeutic potential. To further investigate the impact of Akt1 deficiency on the regulation of dopamine D2 receptor (DRD2) activity and the therapeutic potential of lithium, which is a GSK3 inhibitor, on the alleviation of Akt1-related deficits, a series of 2 studies was conducted. In the study1, microPET imaging with 18F-fallypride revealed the striatal DRD2 activity in male Akt1 heterozygous (Akt1+/-) mice and their wild-type (WT) littermate controls during the periods of adolescence, adulthood, and aging. In the study 2, WT and Akt1+/- females received chronic lithium administration for treating a set of 3 behavioral tasks. In the study 1, our data indicated that alterations of DRD2 activity were found in the striatum of adult but not adolescent or aged mice. And the findings did not result from the dopamine level or DRD2 expression. In the study 2, chronic treatment of lithium alleviated behavioral impairments in the acoustic PPI and tail suspension task in Akt1+/- mice and dampened the Meth-induced stereotypic behaviors in both WT and Akt1+/- females. Collectively, these findings support that Akt1 deficiency predisposes to abnormalities of striatal DRD2 activity contributing to the pathogenesis of comorbid schizophrenia and the therapeutic potential of lithium struggles against the behavioral deficits using Akt1+/- mouse model of schizophrenia. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T05:14:08Z (GMT). No. of bitstreams: 1 ntu-103-R00227112-1.pdf: 2912539 bytes, checksum: e6940c022e6808f9dc715eaaf93b492d (MD5) Previous issue date: 2014 | en |
| dc.description.tableofcontents | Chapter 1 General introduction..........................1
1.The overview of comorbidity of schizophrenia and substance use disorder...................................1 2.The overview of D2 receptor/AKT signaling pathway..39 3.Application of positron emission tomography in animal models of schizophrenia..................................59 4.The Objectives of This Thesis......................77 Chapter 2 Alterations of Striatal Dopamine D2 Receptor Activity with Age-specific Effect in Akt1 Mutant Mouse Model of Schizophrenia Comorbid with Methamphetamine Use Disorder.................................................81 1.Introduction.......................................82 2.Materials and Methods..............................86 3.Results............................................93 4.Discussions........................................99 Chapter 3 Evaluating the therapeutic potential of lithium on the alleviation of behavioral deficits in Akt1 mouse model of schizophrenia..................................113 1.Introduction......................................113 2.Materials and Methods.............................116 3.Results...........................................121 4.Discussions.......................................124 Chapter 4 General discussion...........................135 1.Brief Summaries and contributions of this study...135 2.Potential hypothesis contribute to the vulnerability and pathogenesis of schizophrenia involving with PI3K-Akt1 pathway.................................................138 3.Deregulation of AKT signaling associates with common human diseases comorbid with schizophrenia..............153 4.Lithium Treatment in neurological and neuropsychiatric disorders...............................................158 5.The limitation of this study and future studies...161 Reference...............................................163 | |
| dc.language.iso | en | |
| dc.subject | 思覺失調症 | zh_TW |
| dc.subject | Akt1 | zh_TW |
| dc.subject | 多巴胺二型受體 | zh_TW |
| dc.subject | 甲基安非他命 | zh_TW |
| dc.subject | 行為敏感化 | zh_TW |
| dc.subject | 微正子斷層掃描 | zh_TW |
| dc.subject | 18F-fallypride | zh_TW |
| dc.subject | 鋰鹽 | zh_TW |
| dc.subject | Lithium | en |
| dc.subject | Schizophrenia | en |
| dc.subject | Akt1 | en |
| dc.subject | Dopamine D2 receptor | en |
| dc.subject | Methamphetamine | en |
| dc.subject | Behavioral sensitization | en |
| dc.subject | MicroPET | en |
| dc.subject | 18F-fallypride | en |
| dc.title | 以思覺失調症候選基因Akt1缺損小鼠為模型探討Akt1調控多巴胺二型受體之活性與鋰鹽對於Akt1相關行為缺損之治療效果 | zh_TW |
| dc.title | The Involvement of Akt1 in the Regulation of Striatal Dopamine D2 Receptor Activity and the Rescue Effect of Lithium on Akt1-Related Behavioral Deficits in Akt1 Mutant Mice Model of Schizophrenia | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 102-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 梁庚辰(Keng-Chen Liang),黃宗正(Tzung-Jeng Hwang),廖文霖(Wen-Lin Liao),陳景宗(Jin-Chung Chen) | |
| dc.subject.keyword | 思覺失調症,Akt1,多巴胺二型受體,甲基安非他命,行為敏感化,微正子斷層掃描,18F-fallypride,鋰鹽, | zh_TW |
| dc.subject.keyword | Schizophrenia,Akt1,Dopamine D2 receptor,Methamphetamine,Behavioral sensitization,MicroPET,18F-fallypride,Lithium, | en |
| dc.relation.page | 270 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2014-08-18 | |
| dc.contributor.author-college | 理學院 | zh_TW |
| dc.contributor.author-dept | 心理學研究所 | zh_TW |
| 顯示於系所單位： | 心理學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-103-1.pdf 未授權公開取用 | 2.84 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。